Seeking answers and understanding is the cornerstone of informed civic engagement. Our FAQ page is designed to provide you with clear, comprehensive insights into Sarah Shydale’s policies, motivations, and the practical steps she plans to take to address the pressing issues facing our community.
Reflecting Sarah’s commitment to transparency and open communication, this section aims to equip you with the knowledge to make an informed decision about your representation.
Your inquiries are invaluable to us—they help shape a campaign that’s truly by the people, for the people. If there’s something more you’d like to know, we’re just a message away.
Let’s navigate the path to a brighter, more inclusive future for District 97 together.
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
< answer >
The increasing prevalence of copay accumulator adjustment policies (CAAP) by insurance companies and Pharmacy Benefit Managers (PBMs) is a concern that cannot be overlooked. These policies, as highlighted in the The AIDS Institute’s report on ‘Discriminatory Copay Policies Undermine Coverage for People with Chronic Illness COPAY ACCUMULATOR ADJUSTMENT POLICIES IN 2023,’ clearly outline how CAAPs contribute significantly to the financial burden on patients requiring essential medications. By not counting the funds provided through manufacturer copay assistance programs toward enrollees’ annual deductibles and out-of-pocket limits, insurance companies and PBMs are effectively prioritizing profit over patient well-being. This practice not only undermines the intent of copay assistance programs but also disproportionately impacts those who rely on these medications to maintain their health.
It is alarming that despite the clear negative implications for patients, particularly those with chronic illnesses, federal policies have permitted the growth of CAAPs. The decision by the previous administration to allow health insurance companies and PBMs to use CAAPs at their discretion, even in the absence of a medically appropriate generic alternative, demands urgent reconsideration. While President Biden’s Executive Order to review policies that may present barriers to healthcare is a step in the right direction, immediate action is necessary to reverse the harm caused by CAAPs.
As a candidate for the Indiana House of Representatives, I am committed to advocating for policies that ensure healthcare affordability and accessibility for all Hoosiers. This includes taking a stand against practices like copay accumulator adjustment policies that, while beneficial to insurance company and PBM profits, place an unfair financial strain on patients. Our healthcare system should prioritize the health and well-being of patients over the financial interests of large corporations. If elected, I will work tirelessly to support legislation that addresses these disparities, ensuring that every resident of Indiana has access to the medications they need without undue financial hardship.
< answer >